Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study.

Sci Rep · 2020 · PMC6949213 · PMID 31913293

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

borderline significanceP = 0.090so close (0.05 < p ≤ 0.1)

The CR rates were 16.4% (10/61) in the decitabine group and 6.0% (3/50) in the azacitidine group, with borderline significance ( P = 0.090; Table 2 ).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.